New methods take us closer to targeted, personalised cancer treatment
It is not only tumours and metastases that
differ in each type of cancer and each individual sufferer but also receptors
in cells. It is therefore important to stop thinking of diagnostic methods such
as molecular imaging and pathology, data analysis and ultimately clinical
pharmacology for the development of new drugs as being separate from each other
but instead to combine the individual specialisms and their methods – with the
aim of increasing response rates to effective, personalised cancer treatments.
This was emphasised by experts from MedUni Vienna on the occasion of the first
"Donau
Symposium", a forum for the interdisciplinary development of
cancer treatments that will take place in the Van Swieten Hall of the Medical
University of Vienna from Wednesday to Friday.
This interdisciplinary approach is already
being practised at MedUni Vienna to find targets for cancer diagnosis
and treatment. Molecular imaging at the Division of Nuclear Medicine, in which
drugs, for example, are marked and "glow" in the cell, can be used to
show whether a drug is really working and if it has reached its target.
So-called "liquid biopsies” also allow detailed characterisation of tumour
cells from a blood sample.
"Using
a combination of the two methods, we are in a much better position to represent
the great heterogeneity of tumour cells and their specific characteristics.
This means that diagnostics are much more target-oriented than ever before,"
says Markus Zeitlinger of MedUni Vienna's Department of Clinical Pharmacology.
Moreover, both methods are minimally invasive.
Positive side-effect: the number of
non-responders (patients who do not respond to a drug that is used) is reduced.
“For reasons of health economics as well,
the aim is to reduce this number to zero at some point," explains
Marcus Hacker of MedUni Vienna's Division of Nuclear Medicine. Apart from
nuclear medicine and pharmacology, oncology, health economics, pathology and
the Ludwig Boltzmann Institute Applied Diagnostics are also involved in a
collaborative partnership with MedUni Vienna. "It is precisely this combination of liquid biopsy and targeted
molecular imaging that the Ludwig Boltzmann Institute is developing,"
says Director Marcus Mitterhauser, a radiopharmacist at MedUni Vienna.
Close
collaboration between research and industry
The Donau Symposium, which is taking place
for the first time, aims to promote precisely these cross-disciplinary concepts
on an international level. "We hope that the symposium will offer a forum
for experts from science and industry in the fields of molecular pathology,
nuclear medicine and clinical pharmacology, as well as oncology, with the aim
of discovering effective individualised treatment concepts," says Markus
Zeitlinger.
This close collaboration between research and
industry is also anchored in the plans for the Vienna General Hospital MedUni
campus up to the year 2025: It is hoped that firms – ranging from start-ups,
through innovative SMEs, to national and international industrial concerns –
will establish themselves in MedUni Vienna's planned Technology Transfer
Center. Says Zeitlinger: "This proximity will benefit everybody: the firms
themselves, MedUni Vienna and especially the patients, because it will
facilitate and therefore speed up joint research and development."
Cancer:
5-year survival rate is increasing
In Austria, there are around 39,000 new
cancer cases every year. The mortality rate from cancer is falling: it has
fallen by 1.8% since the year 2000. Nevertheless, around 20,000 Austrians a
year die from cancer. Over the same period, the relative 5-year survival rate
rose from 44% to 61%. The successful cancer research conducted in the
Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital has
brought about massive improvements in the outlook for patients. However, it is
expected that personalised therapeutic approaches will bring significant further
improvements in the near future.
Comments
Post a Comment